By PathGene Biotech · Technically reviewed by Alex Huang
NMN, NAD+, NR, NRHM, NMNH, NADH: A 2026 Buyer's Decision Guide to the NAD+ Precursor Family
If you already know you want “an NAD+ precursor” for your next formulation, the real work starts after that decision, not before it. NMN, NAD+, NR chloride, NRHM, NMNH, and NADH all sit on or around the same metabolic pathway, but they are six chemically distinct raw materials with different solubility, stability, cost, and dosage-form behavior. Picking one because it's the most-searched term, rather than because it fits your formulation and packaging line, is how a stability complaint or a failed tableting trial shows up three months after launch.
Six Forms, One Pathway — Not One Ingredient
All six materials relate to the same NAD+ biosynthetic axis, but the relationship between them is closer to a family tree than a single SKU. NMN is the mononucleotide precursor that the body converts into NAD+, the dinucleotide coenzyme itself. NR chloride and NRHM are two different salt forms of the same nicotinamide riboside nucleoside — same active molecule, different counter-ion. NMNH and NADH are the reduced (dihydro) counterparts of NMN and NAD+ respectively — chemically distinct compounds, not “purer” or “upgraded” versions of their oxidized siblings. Treating any of these as interchangeable names for one ingredient is the first mistake a buyer can make.
Side-by-Side: CAS, Purity, and What Actually Differs
The table below summarizes what can be verified on each material's certificate of analysis and production specification.
| Product | CAS Number | Purity (COA) | Key Differentiator | Typical Use Case |
|---|---|---|---|---|
| NMN | 1094-61-7 | ≥99.5% | Highest COA purity in the family; produced via immobilized-enzyme biocatalysis with no chloride-route contamination; currently the only product in this lineup with USP/EP-aligned certification status | Capsules, sublingual tablets, sachets, general-purpose NAD+ boosting formulations |
| NAD+ | 53-84-9 | ≥98.0% | The dinucleotide coenzyme itself rather than a precursor; larger, more complex molecule produced by fermentation and chromatographic purification | Formulations positioned around NAD+ itself as the label ingredient |
| NR Chloride | 23111-00-4 | ≥98.0% | Chemically synthesized nicotinamide riboside chloride salt; freely water-soluble, established supply chain, but more hygroscopic than the malate form | Capsules, tablets, effervescent formats where cost per kg matters |
| NRHM | 2415659-01-5 | ≥98.0% | Same NR nucleoside, malate (from L-malic acid) counter-ion introduced via patented electrodialysis exchange; markedly lower hygroscopicity than the chloride salt | Direct-compression tablets and humid-climate markets where moisture pickup is a real shelf-life risk |
| NMNH | 108347-85-9 | ≥95.0% | Reduced (dihydro) form of NMN; not found in nature in appreciable amounts; oxygen-sensitive and packed under nitrogen/vacuum to prevent reoxidation back to NMN | Differentiated/premium SKUs built around a reduced-form claim, where the brand controls oxygen exposure through to the finished product |
| NADH | 606-68-8 | ≥98.0% | Reduced disodium salt of NAD+; lyophilized powder requiring light- and moisture-protective handling | Research-reagent and specialty finished-product applications, including diagnostic use cases |
Salt Form Changes How the Powder Behaves
NR chloride and NRHM are the clearest illustration of why “same molecule, different salt” matters operationally. Both deliver the nicotinamide riboside cation; the difference is the counter-ion. The chloride salt has a longer track record and a lower unit cost, but it is more prone to moisture uptake in storage and during processing. NRHM replaces the chloride with a hydrogen malate ion introduced through a controlled electrodialysis ion-exchange step, producing a crystal form associated with markedly lower hygroscopicity. If your production line runs in a humid facility, ships to humid-climate markets, or does direct-compression tableting where moisture pickup causes capping or sticking, that difference is worth the incremental cost. If you're filling capsules in a climate-controlled facility and moving product quickly, the chloride form's lower cost may be the better trade.
Oxidized vs. Reduced: Why NMNH and NADH Need Different Handling
NMNH and NADH are not “next-generation” versions of NMN and NAD+ — they are the reduced counterparts, produced by a separate enzymatic or biocatalytic reduction step, and they carry a genuinely different handling burden. Both are sensitive to oxidation back toward their oxidized form, which is why they're packaged under nitrogen or vacuum and shipped in smaller quantities (100g/500g/1kg vs. 1/5/25kg for the oxidized forms). If you commit to one of these, your own filling and packaging process needs to preserve that oxygen-limited handling all the way to the finished product, or the differentiation you're paying for degrades before it reaches the shelf.
Cost Tier and Lead Time Track Production Complexity
MOQ and lead time aren't arbitrary — they track how forgiving each production route is. NMN's immobilized-enzyme route supports a 1kg MOQ and a 3–5 day lead time. NAD+, NR chloride, and NRHM each involve an extra purification or ion-exchange step and run 5–7 days. NMNH and NADH involve a delicate reduction step with oxygen-limited processing, which is why they ship at 100g minimums with 7–10 day lead times. If your project timeline is tight, that alone should factor into which form you spec for a first order.
How to Actually Decide
Start from the constraint that matters most to your product, not the ingredient name that ranks best in search:
- Solubility/processing: all six are water-soluble to some degree, but hygroscopicity and crystal stability differ — request the appearance and loss-on-drying spec, not just the assay number.
- Label positioning: decide whether your product needs a “precursor” story (NMN, NR, NRHM), the coenzyme itself (NAD+), or a reduced-form story (NMNH, NADH) — these map to different marketing angles and different supply chains.
- Regulatory/standard status: only NMN in this lineup currently carries USP/EP-aligned certification; the rest ship against corporate specification, which is still fully documented but worth confirming against your target market's labeling requirements.
- Sample before you commit: request small samples of your shortlisted forms and run your own compression, dissolution, or stability check before locking in a bulk order.
The six materials aren't competing answers to the same question — they're answers to six different questions about solubility, stability, positioning, and cost. Get the constraint right first, and the choice of form usually becomes straightforward.
Related NAD+ Resources
Explore the NAD+ ingredients hub, or review the NAD+, NADH, NR chloride, and NR malate product pages for current specifications and batch documentation.
Frequently Asked Questions
What's the practical difference between NR chloride and NRHM if they're the same active molecule?+
They deliver the same nicotinamide riboside cation, but with different counter-ions — chloride vs. a hydrogen malate ion introduced via a patented electrodialysis exchange. NRHM's resulting crystal form has markedly lower hygroscopicity, which matters for direct-compression tableting and humid-climate storage; NR chloride has a longer track record and a lower unit cost.
Are NMNH and NADH simply better or purer versions of NMN and NAD+?+
No. They're the reduced (dihydro) counterparts, chemically distinct compounds produced by a separate enzymatic reduction step. They require oxygen-limited processing and packaging and ship in smaller MOQ increments — they're a different product for a different positioning, not an upgrade.
Which of these six products currently carries pharmacopeia-aligned certification?+
Only NMN in this lineup is currently certified against USP/EP standards. NAD+, NR chloride, NRHM, NMNH, and NADH ship against PathGene's corporate specification, with full COA documentation for every batch.
Why do NMNH and NADH have smaller MOQs and longer lead times than the other four?+
Both are produced via an additional enzymatic/biocatalytic reduction step run under oxygen-limited conditions — a more delicate, lower-throughput process than the routes used for the oxidized forms. That's reflected in their 100g MOQ and 7–10 business day lead time, versus 1kg and 3–7 days for the others.
Can I request small samples of multiple forms to test before placing a bulk order?+
Yes. Qualified B2B buyers can request free small samples (typically 10–50g) after business verification, generally enough to run your own solubility, compression, or short-term stability comparison across candidate forms.
Does the salt form (chloride vs. malate) or reduced state need to be disclosed on my finished product label?+
That depends on your target market's labeling regulations, but the ingredient identity in your own documentation should reflect the actual raw material used — if you switch from NR chloride to NRHM, or from NMN to NMNH, the CAS number and chemical name on your records should be updated accordingly.
Ready to evaluate our products?
Request a sample or send an inquiry — our R&D team responds within 24 hours.
